Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12647196 | 0.68 | PGR (0.43) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL15694247 | 0.64 | ATM (0.34) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL15485758 | 0.62 | NQO1 (0.50) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL31001028 | 0.61 | CYP1A2 (0.52) | CYP1A2CYP2A6MAPTKDM4EMAPK1 | |
| SCHEMBL28895790 | 0.60 | CYP1A2 (0.47) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL30661016 | 0.60 | CYP1A2 (0.47) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL11575589 | 0.60 | CYP1A2 (0.47) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL1889878 | 0.60 | PARP1 (0.55) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL599191 | 0.60 | CYP1A2 (0.62) | CYP1A2CYP2A6KDM4EALDH1A1HPGD | |
| SCHEMBL19285741 | 0.59 | CYP1A2 (0.47) | CYP1A2CYP2A6MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124510-A1 | METHODS OF LABELING POLYNUCLEOTIDE WITH DIBENZORHODAMINE DYES | Life Technologies Corporation (US) | 2011-05-26 | — | — | US | disclosed |
| US-7833756-B2 | Methods of labelling polynucleotides with dibenzorhodamine dyes | APPLIED BIOSYSTEMS, LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090068751-A1 | Methods of Labelling Polynucleotides with Dibenzorhodamine Dyes | APPLIED BIOSYSTEMS INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068751-A1 | Methods of Labelling Polynucleotides with Dibenzorhodamine Dyes | NUDT1, DUT, NSUN3 | CYP1A2 3449/4885CYP2A6 2010/4885MAPT 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.